I read the fine print on at-home DNA and health tests - watch out for these risks

This ZDNET article examines privacy, regulatory, and data-use risks posed by direct-to-consumer at-home DNA and health tests—highlighting that many companies may not be covered by HIPAA, that claims like “HIPAA-grade” are marketing language, that de-identified genetic data can often be re-identified or used for research and marketing, and that law enforcement, retention, and insurance implications vary. The piece notes inconsistent FDA involvement and variable clinical interpretation and follow-up, urging consumers to read privacy policies for HIPAA status, data sharing, sample destruction, and law-enforcement disclosure before ordering tests.